Modulators of Small- and Intermediate-Conductance Calcium-Activated Potassium Channels and their Therapeutic Indications
about
The riluzole derivative 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19), a mixed KCa2 activator and NaV blocker, is a potent novel anticonvulsant.The Epac1 signaling pathway regulates Cl- secretion via modulation of apical KCNN4c channels in diarrheaControl of Phasic Firing by a Background Leak Current in Avian Forebrain Auditory Neurons.Rapid Quantification of Mitogen-induced Blastogenesis in T Lymphocytes for Identifying Immunomodulatory DrugsPharmacological gating modulation of small- and intermediate-conductance Ca(2+)-activated K(+) channels (KCa2.x and KCa3.1)Local delivery of the KCa3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis.Mechanosensitive Ca(2+) permeant cation channels in human prostate tumor cells.The relationship between functional inhibition and binding for K(Ca)2 channel blockersInhibition of the K+ channel K(Ca)3.1 reduces TGF-β1-induced premature senescence, myofibroblast phenotype transition and proliferation of mesangial cells.Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressureMolecular and cellular basis of small--and intermediate-conductance, calcium-activated potassium channel function in the brain.Effect of hyperglycemia on brain penetrating arterioles and cerebral blood flow before and after ischemia/reperfusion.The intermediate conductance Ca2+-activated K+ channel inhibitor TRAM-34 stimulates proliferation of breast cancer cells via activation of oestrogen receptors.Differential molecular information of maurotoxin peptide recognizing IK(Ca) and Kv1.2 channels explored by computational simulation.Intermediate-conductance calcium-activated potassium channels participate in neurovascular coupling.KCa3.1 modulates neuroblast migration along the rostral migratory stream (RMS) in vivo.Altered expression and function of small-conductance (SK) Ca(2+)-activated K+ channels in pilocarpine-treated epileptic ratsNS6180, a new K(Ca) 3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease.ESCRT-dependent targeting of plasma membrane localized KCa3.1 to the lysosomesTargeting potassium channels Kv1.3 and KC a 3.1: routes to selective immunomodulators in autoimmune disorder treatment?Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity.Selective activation of KCa3.1 and CRAC channels by P2Y2 receptors promotes Ca(2+) signaling, store refilling and migration of rat microglial cellsA novel pan-negative-gating modulator of KCa2/3 channels, fluoro-di-benzoate, RA-2, inhibits endothelium-derived hyperpolarization-type relaxation in coronary artery and produces bradycardia in vivo.Negative gating modulation by (R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine (NS8593) depends on residues in the inner pore vestibule: pharmacological evidence of deep-pore gating of K(Ca)2 channels.Blocking KCa3.1 channels increases tumor cell killing by a subpopulation of human natural killer lymphocytesHigh glucose induces CCL20 in proximal tubular cells via activation of the KCa3.1 channelRapid throughput analysis demonstrates that chemicals with distinct seizurogenic mechanisms differentially alter Ca2+ dynamics in networks formed by hippocampal neurons in culture.High expression of KCa3.1 in patients with clear cell renal carcinoma predicts high metastatic risk and poor survival.Modulation of K(Ca)3.1 channels by eicosanoids, omega-3 fatty acids, and molecular determinantsRole of ubiquitylation and USP8-dependent deubiquitylation in the endocytosis and lysosomal targeting of plasma membrane KCa3.1.The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression.CyPPA, a Positive SK3/SK2 Modulator, Reduces Activity of Dopaminergic Neurons, Inhibits Dopamine Release, and Counteracts Hyperdopaminergic Behaviors Induced by Methylphenidate.Control of hypothalamic-pituitary-adrenal stress axis activity by the intermediate conductance calcium-activated potassium channel, SK4.KCa3.1-Dependent Hyperpolarization Enhances Intracellular Ca2+ Signaling Induced by fMLF in Differentiated U937 CellsBee Venom Alleviates Motor Deficits and Modulates the Transfer of Cortical Information through the Basal Ganglia in Rat Models of Parkinson's Disease.Inhibition of Myogenic Tone in Rat Cremaster and Cerebral Arteries by SKA-31, an Activator of Endothelial KCa2.3 and KCa3.1 Channels.Altered calcium signaling following traumatic brain injuryTherapeutic potential of KCa3.1 blockers: recent advances and promising trends.Microglial KCa3.1 Channels as a Potential Therapeutic Target for Alzheimer's DiseaseMolecular overlap in the regulation of SK channels by small molecules and phosphoinositides
P2860
Q27339255-2178A8E4-0BEB-4977-8348-46EFCF77B34EQ28385670-04D3E94A-D62F-4570-9844-3EF2C22E03BDQ28606523-A4D44C15-3E68-405D-98BF-8ADB4CB91356Q28817533-EC4A51E7-BEDD-4BD6-9DEF-EDD89B3824ABQ28833834-C6DB9183-FED5-4CAE-9B2B-38074D2EA3A4Q30440082-B8CD8F1B-5E5C-4053-AC89-ED2051E34635Q30528750-F784FCB6-DBCE-4DFE-BEAB-C6F0B8992757Q31138627-228BF074-1A58-422A-913C-1C846C304D6EQ31149306-52E03D00-E8CE-4C7F-9CF2-95D4ECD5A36EQ33379783-886C556D-0AE2-40C7-90C6-3D01FC64F154Q33560844-11577C2E-CD36-4149-BA8F-22DE66A7FAEBQ33610057-FB352861-574F-4820-8319-26DE5E242F0BQ33685939-623E037A-E658-420B-AB13-F3F66B9EFC20Q33801747-E1524B27-A042-41F5-B5C9-EA5AD6DF776EQ33877765-C3E72998-AC06-4521-93E7-60B0B7A0836FQ34027793-15BE2872-BE13-4DA1-A794-1B82FAC36117Q34047643-8C8F257D-6708-4C42-8A35-23E49ED87A3CQ34293957-5DEE1B31-4508-40EA-99EF-66F6E3302088Q34304952-9189684E-055F-4B4C-A73E-8780F05A615CQ34343254-7ED17A2D-A814-4D58-AA2F-BE08EA063AAAQ34536960-C32470E1-E849-49FF-A62D-205DCC0FF600Q34689609-89873D43-BD23-424C-AB19-DDF62839F9F1Q34946861-857EBD5A-EF6E-4B6A-987F-B3B7E3C72EECQ35008894-451CC151-16B3-45F4-94A8-3FC865461198Q35022931-2FCD3F76-D7EA-43DF-BDCA-FD8D13CC9029Q35147905-F9E12E46-A7CF-4D44-BCFB-DCD2992DCAC8Q35198051-91B9A313-26D6-4CC4-9DE5-C164B1549EFDQ35304761-6E320D3E-414E-4D4C-86A4-008C19C07A38Q35395940-95F2776C-8F57-47A0-99F4-3F97AD05E799Q35497084-E83F19D4-BDC5-412F-B3DF-B3C6963949C3Q35660234-F4AB500E-DF60-4400-B801-EA10BDFC956DQ35752533-6D48B644-BFB7-4A1B-A2B8-1621982B3F69Q35778134-89A42A8D-C781-4138-960A-E0D930BC616CQ35792037-C16E0543-C0D4-4F45-8F52-D6887F39B6BEQ35842101-34C09FF1-06DD-4107-9727-DFB528D93D69Q35847147-131528B5-3FA0-4080-8934-BBD101EF9AFAQ35885083-8DCDEDAE-8E07-418A-9E64-01F8E8258849Q35944615-C8529C37-C2A4-4A92-9D19-9E7E970D0EDCQ35999547-83AEA59F-2084-489C-B5C7-B5BDEFFF727AQ36040703-260FD52F-8666-46AF-A500-D1AF779E98CF
P2860
Modulators of Small- and Intermediate-Conductance Calcium-Activated Potassium Channels and their Therapeutic Indications
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Modulators of Small- and Inter ...... their Therapeutic Indications
@ast
Modulators of Small- and Inter ...... their Therapeutic Indications
@en
Modulators of Small- and Inter ...... their Therapeutic Indications
@en-gb
type
label
Modulators of Small- and Inter ...... their Therapeutic Indications
@ast
Modulators of Small- and Inter ...... their Therapeutic Indications
@en
Modulators of Small- and Inter ...... their Therapeutic Indications
@en-gb
prefLabel
Modulators of Small- and Inter ...... their Therapeutic Indications
@ast
Modulators of Small- and Inter ...... their Therapeutic Indications
@en
Modulators of Small- and Inter ...... their Therapeutic Indications
@en-gb
P2093
P3181
P1476
Modulators of small- and inter ...... their therapeutic indications
@en
P2093
Aaron Kolski-Andreaco
Ananthakrishnan Sankaranarayanan
Heike Wulff
Vikram Shakkottai
P304
P3181
P356
10.2174/092986707780831186
P577
2007-01-01T00:00:00Z